Presentation is loading. Please wait.

Presentation is loading. Please wait.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Published byRidwan Susman Modified over 5 years ago

Similar presentations

Presentation on theme: "Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical."— Presentation transcript:

1 Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Whereas several nonselective FGFR inhibitors have entered phase II/III trials, selective FGFR inhibitors are mostly in early-phase development programs. Phase II trials with genomic enrichment are ongoing with the selective FGFR inhibitors AZD4547 and BGJ398. Mehdi Touat et al. Clin Cancer Res 2015;21: ©2015 by American Association for Cancer Research

Download ppt "Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical."

Similar presentations

The expression and signaling of FGFR3 in WM cells.

The expression and signaling of FGFR3 in WM cells.
© The Author(s) Published by Science and Education Publishing.

© The Author(s) Published by Science and Education Publishing.
Endocrine Combinations in HR-Positive MBC: The Future Is Now

Endocrine Combinations in HR-Positive MBC: The Future Is Now
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Tailoring Hemophilia Prophylaxis Therapy

Tailoring Hemophilia Prophylaxis Therapy
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Potential clinical actionability.

Potential clinical actionability.
Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola 

Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola 
ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.

ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.
Checkpoint Inhibitors in First-Line Advanced NSCLC

Checkpoint Inhibitors in First-Line Advanced NSCLC
Schematic depiction of CTC processing methods.

Schematic depiction of CTC processing methods.
A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.

A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.
BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.

BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.
Effect of nucleoside analogues on DNA repair response initiated by 4-HC. Effect of nucleoside analogues on DNA repair response initiated by 4-HC. A, CLL.

Effect of nucleoside analogues on DNA repair response initiated by 4-HC. Effect of nucleoside analogues on DNA repair response initiated by 4-HC. A, CLL.
A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

Similar presentations

Ads by Google